To assess the 3-year outcome of half-dose verteporfin photodynamic therapy (PDT) in central serous chorioretinopathy (CSC) with optical coherence tomography angiography (OCT-A) detected choroidal neovascularization (CNV), we performed a retrospective, interventional study. Patients were divided into 2 groups according to the fluorescein angiography: point source leakage in group 1 and diffuse oozing in group 2. Data were collected from patients including changes of best-corrected visual acuity (BCVA), size of CNV, central macular thickness (CMT), choroidal thickness (CT), reabsorption of subretinal fluid (SRF), sessions of half-dose PDT, and the number of intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF). There was a total of 34 eyes in 32 patients included. The mean sessions of half-dose PDT was 1.50 ± 0.75. The mean number of IVI of anti-VEGF was 1.38 ± 3.34. BCVA improved from 0.38 ± 0.33 to 0.20 ± 0.22 (p < 0.001). Mean CMT was significantly reduced along with reduced CT and increased size of CNV. SRF was totally reabsorbed in 31 eyes. Patients in group 1 had significant less sessions of PDT and better final BCVA. In conclusion, half-dose PDT treatment was effective for CSC with CNV. Patients with diffuse oozing in FA may fare less well with half-dose PDT.

为了通过光学相干断层扫描血管造影 (OCT-A) 检测脉络膜新生血管 (CNV) 评估半剂量维替泊芬光动力疗法 (PDT) 治疗中央浆液性脉络膜视网膜病变 (CSC) 的 3 年结果，我们进行了一项回顾性、介入性研究。根据荧光血管造影将患者分为2组：第1组为点源性渗出，第2组为弥漫性渗出。 收集患者的数据，包括最佳矫正视力（BCVA）、CNV大小、中央黄斑厚度（ CMT)、脉络膜厚度 (CT)、视网膜下液 (SRF) 的重吸收、半剂量 PDT 的疗程以及抗血管内皮生长因子 (抗 VEGF) 的玻璃体内注射 (IVI) 次数。共纳入32例患者34只眼。半剂量 PDT 的平均疗程为 1.50 ± 0.75。抗VEGF的IVI平均数为1.38±3.34。BCVA 从 0.38 ± 0.33 提高到 0.20 ± 0.22 (p  < 0.001)。平均 CMT 显着降低，同时 CT 降低和 CNV 大小增加。SRF 在 31 只眼中被完全重吸收。第 1 组患者的 PDT 疗程显着减少，最终 BCVA 更好。总之，半剂量 PDT 治疗对伴有 CNV 的 CSC 有效。FA 弥漫性渗出的患者在接受半剂量 PDT 治疗时效果可能较差。